NewLimit, a startup that goals to extend how lengthy folks can reside a wholesome life by genetically programming their cells, has raised a $130 million Sequence B led by Kleiner Perkins.
New buyers Nat Friedman, Daniel Gross, and Khosla Ventures additionally invested, as did returning backers Founders Fund, Dimension Capital, Elad Gil, Garry Tan, Patrick Collison, and others. The fundraise comes two years after the corporate raised a $40 million Sequence A.
Based over 4 years in the past by Coinbase CEO Brian Armstrong (pictured above), former GV associate Blake Byers, and stem cell professor Jacob Kimmel, NewLimit claims it has made vital progress towards growing remedies that may restore youthful traits to aged cells.
Byers instructed TechCrunch the corporate has found three prototype medicines that reprogram liver cells. NewLimit’s lab experiments, he mentioned, show this rejuvenation can restore the cells’ means to course of fats and alcohol.
The corporate measures its progress by contrasting how cells from a youthful particular person and an older particular person reply to the substances. An older liver cell that has gone by means of NewLimit’s epigenetic reprogramming behaves extra like a youthful cell, Byers mentioned.
Promising early outcomes however, NewLimit continues to be just a few years away from beginning human trials.
Within the meantime, the corporate desires to proceed growing new anti-aging medication utilizing an AI mannequin after which testing probably the most promising of those machine-generated medicine in its laboratory. “What the AI mannequin permits us to do is run all these experiments in simulation after which solely observe up on probably the most promising subset,” Byers mentioned, including that the info factors from the experiment are then used to retrain the AI mannequin in a course of referred to as “lab in a loop.”
Techcrunch occasion
Berkeley, CA
|
June 5
BOOK NOW
Different noteworthy biotech startups growing medicine that purpose to extend lifespan embrace Retro Biosciences, which raised $180 million from OpenAI CEO Sam Altman two years in the past and is reportedly elevating a $1 billion Sequence A; and Altos Labs, which launched with $3 billion in 2022 and is backed by Jeff Bezos.